Clinical profiles of 7 patients with multicentric form of Castleman's disease who received humanized anti-IL-6R Ab therapy
| Patient . | Age/ Sex . | Disease Duration* (years) . | Histologic Diagnosis† . | Complications† . | Total Amount of Anti-IL-6R Ab (mg) . | Number of Administrations . | Duration of Anti-IL-6R Ab Therapy (mo) . | Concominant Therapy† . | Serum IL-6 Concentration Before Therapy (pg/mL)‡ . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 33/M | 3 | Mixed type | LIP | 4561 | 67 | 11 | Pred 10 mg | 40.1 |
| 2 | 43/F | 1 | Plasma cell type | LIP | 4060 | 46 | 10 | (−) | 93.0 |
| 3 | 59/F | 1 | Plasma cell type | Secondary amyloidosis | 1661 | 35 | 4 | (−) | 44.1 |
| 4 | 23/M | 1 | Mixed type | Secondary amyloidosis LIP | 1860 | 25 | 4 | (−) | 20.6 |
| 5 | 51/M | 3 | Plasma cell type | Secondary amyloidosis | 1200 | 26 | 41-153 | Pred 10 mg | 6.5 |
| l-PAM 2 mg | |||||||||
| 6 | 54/F | 1 | Plasma cell type | LIP | 660 | 15 | 2 | Pred 40 mg | 8.4 |
| CYC 50 mg | |||||||||
| 7 | 49/F | 1 | Plasma cell type | LIP | 410 | 10 | 1 | Pred 20 mg | 24.5 |
| Patient . | Age/ Sex . | Disease Duration* (years) . | Histologic Diagnosis† . | Complications† . | Total Amount of Anti-IL-6R Ab (mg) . | Number of Administrations . | Duration of Anti-IL-6R Ab Therapy (mo) . | Concominant Therapy† . | Serum IL-6 Concentration Before Therapy (pg/mL)‡ . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 33/M | 3 | Mixed type | LIP | 4561 | 67 | 11 | Pred 10 mg | 40.1 |
| 2 | 43/F | 1 | Plasma cell type | LIP | 4060 | 46 | 10 | (−) | 93.0 |
| 3 | 59/F | 1 | Plasma cell type | Secondary amyloidosis | 1661 | 35 | 4 | (−) | 44.1 |
| 4 | 23/M | 1 | Mixed type | Secondary amyloidosis LIP | 1860 | 25 | 4 | (−) | 20.6 |
| 5 | 51/M | 3 | Plasma cell type | Secondary amyloidosis | 1200 | 26 | 41-153 | Pred 10 mg | 6.5 |
| l-PAM 2 mg | |||||||||
| 6 | 54/F | 1 | Plasma cell type | LIP | 660 | 15 | 2 | Pred 40 mg | 8.4 |
| CYC 50 mg | |||||||||
| 7 | 49/F | 1 | Plasma cell type | LIP | 410 | 10 | 1 | Pred 20 mg | 24.5 |
Disease duration is defined as the period since diagnosis.
Pred indicates prednisolone; CYC, cyclophosphamide;l-PAM, melphalan; mixed type, mixed plasma cell and hyaline vascular type; LIP, lymphocytic interstitial pneumonia.
Normal range of serum IL-6 is < 1 pg/ml.
The patient received anti-IL-6R antibody therapy for a total of 4 months after a 2-month interval.